Ignite Creation Date:
2024-05-06 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 2:24 PM
Study NCT ID:
NCT05237349
Status:
RECRUITING
Last Update Posted:
2024-01-05
First Post:
2022-01-18
Brief Title:
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Sponsor:
Liangjun Zhu MM
Organization:
Jiangsu Cancer Institute Hospital
Study Overview
Official Title:
A Prospective Single-arm Clinical Trial of Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective is to investigate the efficacy and safety of Envafolimab combined with chemotherapy in the treatment of metastatic or recurrent gastric adenocarcinoma
Detailed Description:
Envafolimab indication Envafolimab is the worlds first subcutaneous injection of PD-L1 monoclonal antibodySuitable for adult patients with advanced solid tumors with unresectable or metastatic microsatellite highly unstable MSI-H or mismatch repair gene defects dMMR
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None